Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
PremiumPress ReleasesEditas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
2M ago
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
PremiumPress Releases
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
2M ago
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
PremiumPress Releases
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
3M ago
Editas Medicine upgraded to Equal Weight from Underweight at Morgan Stanley
PremiumThe FlyEditas Medicine upgraded to Equal Weight from Underweight at Morgan Stanley
3M ago
Editas Medicine reports Q1 EPS (76c), consensus (66c)
PremiumThe Fly
Editas Medicine reports Q1 EPS (76c), consensus (66c)
3M ago
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
PremiumPress Releases
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100